CH0346177709 - Common Stock - After market: 0.2115 0 (-0.52%)
NASDAQ:OBSV (1/27/2023, 7:25:41 PM)+0.01 (+2.56%)
GICS Sector | Health Care | ||
GICS Industry | Biotechnology |
Valuation | Growth | ||
Profitability | Health | ||
Dividend |
Earnings (Last) | 12-01 2022-12-01/amc | Earnings (Next) | 03-06 2023-03-06 |
Ins Owners | 2.48% | Inst Owners | 16.17% |
Market Cap | 17.96M | Shares | 84.50M |
PE | N/A | Fwd PE | N/A |
Dividend Yield | N/A | Analysts | 77.78 |
IPO | 07-13 2018-07-13 |
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 51 full-time employees. The company went IPO on 2018-07-13. The firm develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and uterine fibroids; Nolasiban (OBE001), an oral oxytocin receptor antagonist, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor.
OBSEVA SA
Chemin des Aulx 12
Plan-les-Ouates GENEVE 1228
P: 41225521558.0
CEO: Brian O'Callaghan
Employees: 51
Website: http://www.obseva.com/
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 19, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 14, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a...
ObsEva SA (OBSV) announced Friday that its board decided to increase the share capital through the issuance of newly registered shares in a bid to raise funds. Read the full story here.
Here you can normally see the latest stock twits on OBSV, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: